Abstract
Introduction:
Hepatitis B virus (HBV) reactivation is a majorcause of morbidity and mortality in patients with hematologicalmalignancies who receive cytotoxic chemotherapy. Wehave therefore carried out a prospective observational studyout to assess the incidence, prevalence, and clinical course ina cohort of these patients.
Methods:
HBV and HCV markers and liver function indiceswere monitored prospectively in 318 consecutive patients(171 males, 147 females; mean age 57 years) with hematologicalmalignancies, who had been referred to the HematologyDivision, Perugia University, between October 2005and March 2007 and followed up for at least 6 months.
Results:
At diagnosis, 32 patients (10%) had received HBVvaccination; 30 were responders. At least one HBV marker waspositive in 70/318 patients (22%): 14 (20%) were HBsAg-positive(HBV surface antigen-positive), 13 (19%) were only anti-HBc positive (antibodies to HB core antigen), and 43(61%)were anti-HBc and anti-HBs positive. Twelve HBsAg+ patientsreceived nucleoside/nucleotide analogs (adefovir [six patients],lamivudine [four], and combined adefovir/lamivudine[two non-responders to lamivudine]). After 6 months oftherapy, HBV-DNA was negative and transaminases were normalin nine of these 12 patients (adefovir [six], lamivudina[two], adefovir + lamivudina [one]). Seroreversion wasachieved in 3/13 patients (23%) who were only anti-HBc positive;all were on rituximab therapy and received adefovir.Seroreversion was not observed in any of the 43 patients whowere anti-HBc- and anti-HBs positive.
Conclusions:
Essential to the management of patients withhematological malignancies undergoing chemotherapy aresurveillance and prophylaxis of HBV infection together withprompt administration of nucleoside/nucleotide analogs incases of reactivation and/or seroreversion.
Similar content being viewed by others
References
Liang R, Lau GK, Kwong YL: Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 1999; 17: 394–398.
Xunrong L, Yan AW, Liang R, Lau GK: Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy — pathogenesis and management. Rev Med Virol 2001; 11: 287–299.
Galbraight RM, Eddleston AL, Williams R, et al. Fulminating hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528–530.
Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infections in haematological malignancies and liver injury ollowing chemotherapy. European J Haematol 2005; 74: 156–163.
Hoofnagle JH, Dusheiko Gm, Schafer DF, R, Gerber MA, Klian F, et al.: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 446–449.
Xunrong L, Yan AW, Liang R, et al. Hepatitis B virus (HBV) reactivation after cytotoxic or immunosoppressive therapypathogenesis and management. Rev Med Virol 2001; 11: 287–299.
Galbraight RM, Eddleston AL, Williams R, et al. Fulminating hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528–530.
Thung SN, Gerber MA, Klion F, et al. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B carrier. Arch Intern Med 1985; 145: 1313–1314.
Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991; 100: 182–188.
Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liv Dis 2007; 39: 397–408.
Iwai K, Tashima M, Itoh M, et al. Fulminant hepatitis B following bone marrow transplantation in an HbsAg-negative, HbsAb positive recipient; reactivation of dormant virus during the immunosuppressive period. Bone Marrow transplant 2000; 25: 105–108.
Raimondo G, Pollicino T, Cacciolla I, et al. Occult hepatitis B infection. J Hepatol 2007; 46: 160–170.
Cheng AL, Hsiung CA, Su LJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003; 37: 1320–1328.
Tsutsumi Y, Kanamori H, Mori A, et al. Reactivationof hepatitis B virus with rituximab. Expert Opinion on Drug Safety 2005; 4: 599–610.
Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alentuzumab therapy. Eur J Haematol 2005; 74: 254–258.
Sarrecchia C, Cappelli A, Aiello P, et al. HBV reactivation with fatal fulminant hepatitis during rituximab treatment in a subject negative for HbsAg and positive for HbsAb and HbcAb. J Infect Chemother 2005; 11: 189–191.
Lee WM: Hepatitis B virus infection. New Engl J Med 1997; 337: 1733–1745.
Karayiannis P: Current therapies for chronic hepatitis B virus infection. Expert Rev Anti Infect Ther 2004; 2: 745–760.
Ramazam I: Lamivudine prophylaxis in HBV carriers with haemato-oncological malignances who receive chemotherapy. J Antimicrob Chemother 2005; 55: 828–831.
Perez-Roldan F, Gonzalez-Carro P, Villafanez-Garcia MC: Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med 2005; 352: 310–311.
Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679–693.
Colson P, Borentain P, Coso D et al.: Entecavir as a first-line treatment for HBV reactivation following polychemotherapy for lymphoma. Br J Haematol 2008; 148–150.
Ming-Shen D, Tsu-Yi C, Woei-Yau K, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004; 83: 769–774.
Lin PC, Poh SB, Lee MY, et al. Fatal fulminant hepatitis B after withdrawal of prophylactic Lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol 2005; 81: 340–351.
Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007; 45: 507–539.
Mason AL, Xu L, Guo L, et al. Molecular basis for persistent hepatitis B infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736–1742.
Marusawa H, Uemoto S, Hijikata M, et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488–495.
Mihm V, Gärtner BC, Faust D, et al. Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. J Hepatol 2005; 43: 217–224.
Marcucci F, Mele A, Spada E, et al. High prevalence of hepatitis B virus infection in B-cell non Hodgkin’s lymphoma. Haematologica 2006; 9: 554–557.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Francisci, D., Falcinelli, F., Schiaroli, E. et al. Management of Hepatitis B Virus Reactivation in Patients with Hematological Malignancies Treated with Chemotherapy. Infection 38, 58–61 (2010). https://doi.org/10.1007/s15010-009-9019-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-009-9019-1